Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: July 12, 2011
Last updated: October 14, 2014
Last verified: October 2014

This study is designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of perampanel on Primary Generalized Tonic Clonic (PGTC) seizure frequency in adolescents and adults maintained on one to two stable antiepileptic drugs.

Condition Intervention Phase
Seizure Disorder Generalized Tonic Clonic
Drug: perampanel
Drug: placebo comparator
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Percent change from baseline in PGTC seizure frequency per 28 days [ Time Frame: from baseline over the Titration and Maintenance Periods (17 weeks) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Responder Rate for all subtypes of primary generalized seizure frequency per 28 days [ Time Frame: Maintenance Period relative to baseline (17 weeks) ] [ Designated as safety issue: No ]

Estimated Enrollment: 165
Study Start Date: September 2011
Estimated Study Completion Date: April 2017
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: perampanel Drug: perampanel
up to 8 mg, oral tablet, once daily
Placebo Comparator: placebo Drug: placebo comparator
oral tablet, once daily


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


Ages 12 years and older

  1. Clinical diagnosis of PGTC seizures (with or without other subtypes of primary generalized seizures) and experiencing greater than or equal to 3 PGTC seizures during the 8-week period prior to randomization
  2. Have had a routine electroencephalogram (EEG) prior to or during the Baseline Period with electroencephalographic features consistent with primary generalized epilepsy; other concomitant anomaly should be explained by adequate past medical history
  3. On a fixed dose of one to a maximum of three concomitant antiepileptic drugs (AEDs) for a minimum of 30 days prior to Baseline; only one inducer AED (i.e., carbamazepine, oxcarbazepine, or phenytoin) out of the maximum of two AEDs will be allowed
  4. A vagal nerve stimulator (VNS) will be allowed, but it must have been implanted greater than or equal to 5 months prior to Baseline (stimulator parameters cannot be changed for 30 days prior to Baseline and for the duration of the study).
  5. Have had a computed tomography (CT) or magnetic resonance imaging (MRI) within the last 10 years (for adults) and 5 years (for adolescents) that ruled out a progressive cause of epilepsy
  6. A ketogenic diet will be allowed as long as the subject has been on this diet for 5 weeks prior to randomization


  1. A history of status epilepticus that required hospitalization within 12 months prior to Baseline
  2. Seizure clusters where individual seizures cannot be counted
  3. A history of psychogenic seizures
  4. Concomitant diagnosis of Partial Onset Seizures (POS)
  5. Progressive neurological disease
  6. Clinical diagnosis of Lennox-Gastaut syndrome
  7. If felbamate is used as a concomitant AED, subjects must be on felbamate for at least 2 years, with a stable dose for 60 days prior to Baseline. They must not have a history of white blood cell (WBC) count below less than or equal to 2500/microL (2.50 1E+09/L), platelets less than 100,000/microL, liver function tests (LFTs) greater than 3 times the upper limit of normal (ULN), or other indication of hepatic or bone marrow dysfunction while receiving felbamate.
  8. Concomitant use of vigabatrin: Subjects who took vigabatrin in the past must be discontinued for approximately 5 months prior to Baseline, and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test
  9. Concomitant use of barbiturates (except for seizure control indication) within 30 days prior to Baseline
  10. Use of intermittent rescue benzodiazepines (i.e., one to two doses over a 24-hour period considered one-time rescue) two or more times within the 30 days prior to Baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01393743

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
San Francisco, California, United States
Santa Monica, California, United States
United States, Colorado
Aurora, Colorado, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, Florida
Bradenton, Florida, United States
Gulf Breeze, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Tampa, Florida, United States
United States, Georgia
Boston, Georgia, United States
United States, Idaho
Boise, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
United States, Kansas
Wichita, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Minnesota
Golden Valley, Minnesota, United States
United States, Missouri
Chesterfield, Missouri, United States
United States, New Jersey
Neptune, New Jersey, United States
United States, New York
Al bany, New York, United States
Buffalo, New York, United States
New York, New York, United States
United States, Ohio
Akron, Ohio, United States
Toledo, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
Temple, Texas, United States
United States, Wisconsin
Madison, Wisconsin, United States
Camperdown, Australia
Fitzroy, Australia
Heidelberg, Australia
Parkville, Australia
Randwick, Australia
Graz, Austria
Innsbruck, Austria
Salzburg, Austria
Wien, Austria
Changchun, China
Chengdu, China
Chongqing, China
Guangzhou, China
Ji'nan, China
Nanchang, China
Nanjing, China
Shanghai, China
Taiyuan, China
Wuhan, China
Xi'an, China
Xian, China
Czech Republic
Hradec Kralove, Czech Republic
Ostrava, Czech Republic
Praha 2, Czech Republic
Lyon, France
Nancy, France
Paris Cedex 19, France
Toulouse, France
Berlin, Germany
Bernau, Germany
Bielefeld, Germany
Bonn, Germany
Erlangen, Germany
Kehl-Kork, Germany
Mainz, Germany
Marburg, Germany
Munchen, Germany
Tubingen, Germany
Ulm, Germany
Athens, Greece
Patras, Greece
Thessaloniki, Greece
Budapest, Hungary
Kecskemet, Hungary
Pecs, Hungary
Bangalore, India
Hyderabad, India
Lucknow, India
Mangalore, India
New Delhi, India
Secunderabad, India
Visakhapatnam, India
Haifa, Israel
Holon, Israel
Nahariya, Israel
Petach Tikva, Israel
Ramat Gan, Israel
Aomori, Japan
Gumma, Japan
Higashiosaka, Japan
Hiroshima, Japan
Kanagawa, Japan
Kitakyushu, Japan
Matsue, Japan
Matsuyama, Japan
Nara, Japan
Nerima-ku, Japan
Niigata, Japan
Obihiro, Japan
Sakai, Japan
Sapporo, Japan
Sendai, Japan
Tokushima, Japan
Tokyo, Japan
Toyama, Japan
Ube, Japan
Uji, Japan
Yamaga, Japan
Korea, Republic of
Busan, Korea, Republic of
Daegu, Korea, Republic of
Seoul, Korea, Republic of
Riga, Latvia
Valmiera, Latvia
Vilnius, Lithuania
Den Haag, Netherlands
Heeze, Netherlands
Rotterdam, Netherlands
Gdansk, Poland
Katowice, Poland
Krakow, Poland
Poznan, Poland
Warszawa, Poland
Belgrade, Serbia
Bangkok, Thailand
Muang, Thailand
Sponsors and Collaborators
Eisai Inc.
Study Director: Francesco Bibbiani Eisai Inc.
  More Information

No publications provided

Responsible Party: Eisai Inc. Identifier: NCT01393743     History of Changes
Other Study ID Numbers: E2007-G000-332
Study First Received: July 12, 2011
Last Updated: October 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Eisai Inc.:
Central Nervous System

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms processed this record on November 20, 2014